Skip to main content
Erschienen in: Targeted Oncology 1/2014

01.03.2014 | Original Research

Partial response of a rare malignant metastatic diffuse tenosynovial giant cell tumor with benign histologic features, treated with SCH 717–454, an insulin growth factor receptor inhibitor, in combination with everolimus, an MTOR inhibitor

verfasst von: Swati Sikaria, Josefine Heim-Hall, Elizabeth H. Diaz, Ronald Williams, Kamelesh Sankhala, Brenda Laabs, Monica Mita

Erschienen in: Targeted Oncology | Ausgabe 1/2014

Einloggen, um Zugang zu erhalten

Excerpt

Tenosynovial giant cell tumor (TGCT) is a neoplastic proliferation arising in tendon sheath, bursa, and/or synovium. Decades ago, it was thought to be an inflammatory process, owing to the presence of large numbers of macrophages within the tumor. However, TGCT is now considered a neoplastic process composed of compact foci of polyhedral cells with varying numbers of multinucleated giant, lipid, and hemosiderin-laden cells. These tumors can be subdivided based on the degree of synovial involvement into localized (circumscribed) or diffuse forms. Localized TGCT tends to occur in the finger and is nodular. Though it may recur, it is generally amenable to local resection. On the other hand, diffuse type TGCT more frequently affects larger joints, especially the knee and wrist. This diffuse type can be intra-articular (also called pigmented villonodular tenosynovitis) or extra-articular, and is notoriously difficult to control with local resection, tending to recur frequently. …
Literatur
1.
Zurück zum Zitat Li CF, Wang J, Huang W, Hou C, Chou S, Eng JH, Lin C, Yu S, Huang H (2008) Malignant diffuse-type tenosynovial giant cell tumors: a series of 7 cases comparing with 24 benign lesions with review of the literature. Am J Surg Pathol 32:587–599PubMedCrossRef Li CF, Wang J, Huang W, Hou C, Chou S, Eng JH, Lin C, Yu S, Huang H (2008) Malignant diffuse-type tenosynovial giant cell tumors: a series of 7 cases comparing with 24 benign lesions with review of the literature. Am J Surg Pathol 32:587–599PubMedCrossRef
2.
Zurück zum Zitat Cassier JA, Blay JY et al (2012) Efficacy of imatinib mesylate for the treatment of locally advanced and/or metastatic tenosynovial giant cell tumor/pigmented villonodular synovitis. Cancer 118(6):1649–1655PubMedCrossRef Cassier JA, Blay JY et al (2012) Efficacy of imatinib mesylate for the treatment of locally advanced and/or metastatic tenosynovial giant cell tumor/pigmented villonodular synovitis. Cancer 118(6):1649–1655PubMedCrossRef
3.
Zurück zum Zitat Somerhausen N, Fletcher C (2000) Diffuse-type giant cell tumor clinicopathologic and immunohistochemical analysis of 50 cases with extraarticular disease. Am J Surg Path 24(4):479–492PubMedCrossRef Somerhausen N, Fletcher C (2000) Diffuse-type giant cell tumor clinicopathologic and immunohistochemical analysis of 50 cases with extraarticular disease. Am J Surg Path 24(4):479–492PubMedCrossRef
4.
Zurück zum Zitat Ravi V, Wang W, Lewis VO (2011) Treatment of tenosynovial giant cell tumor and pigmented villondular synovitis. Curr Opin Oncol 23:361–366PubMedCrossRef Ravi V, Wang W, Lewis VO (2011) Treatment of tenosynovial giant cell tumor and pigmented villondular synovitis. Curr Opin Oncol 23:361–366PubMedCrossRef
5.
Zurück zum Zitat Chin KR, Barr SJ, Winalski C et al (2002) Treatment of advanced primary and recurrent diffuse pigmented villonodular synovitis of the knee. J Bone Joint Surg Am 84-A:2192–2202PubMed Chin KR, Barr SJ, Winalski C et al (2002) Treatment of advanced primary and recurrent diffuse pigmented villonodular synovitis of the knee. J Bone Joint Surg Am 84-A:2192–2202PubMed
6.
Zurück zum Zitat Cheng H, Clarkson PW, Gao D, Pacheco M, Wang Y, Nielson TO (2010) Therapeutic antibodies targeting CSF1 impede macrophage recruitment in a xenograft model of tenosynovial giant cell tumor. Sarcoma. doi:10.1155/2010/174528 Cheng H, Clarkson PW, Gao D, Pacheco M, Wang Y, Nielson TO (2010) Therapeutic antibodies targeting CSF1 impede macrophage recruitment in a xenograft model of tenosynovial giant cell tumor. Sarcoma. doi:10.​1155/​2010/​174528
7.
Zurück zum Zitat Khandwala HM, McCutcheon IE, Flyvbjerg A, Friend KE (2000) The effects of insulin-like growth factors on tumorigenesis and neoplastic growth. Endocr Rev 21(3):215–244PubMedCrossRef Khandwala HM, McCutcheon IE, Flyvbjerg A, Friend KE (2000) The effects of insulin-like growth factors on tumorigenesis and neoplastic growth. Endocr Rev 21(3):215–244PubMedCrossRef
8.
Zurück zum Zitat Giustina A, Mazziotti G, Canalis E (2006) Growth hormone, insulin-like growth factors, and the skeleton. Endocr Rev 29(5):535–559CrossRef Giustina A, Mazziotti G, Canalis E (2006) Growth hormone, insulin-like growth factors, and the skeleton. Endocr Rev 29(5):535–559CrossRef
9.
Zurück zum Zitat Myers MG Jr, Sun XJ, Cheatham B, Jachna BR, Glasheem EM, Backer JM, White MF (1993) IRS-1 is a common element in insulin and insulin-like growth factor-1 signaling to the phosphatidylinositol 3′-kinase. Endocrinology 132:1421–1430PubMed Myers MG Jr, Sun XJ, Cheatham B, Jachna BR, Glasheem EM, Backer JM, White MF (1993) IRS-1 is a common element in insulin and insulin-like growth factor-1 signaling to the phosphatidylinositol 3′-kinase. Endocrinology 132:1421–1430PubMed
10.
Zurück zum Zitat Raile K, Höflich A, Kessler U et al (1994) Human osteosarcoma (U-2 OS) cells express both insulin-like growth factor-I (IGF-I) receptors and insulin-like growth factor-II/mannose-6-phosphate (IGF-II/M6P) receptors and synthesize IGF-II: autocrine growth stimulation by IGF-II via the IGF-I receptor. J Cell Physiol 159(3):531–541PubMedCrossRef Raile K, Höflich A, Kessler U et al (1994) Human osteosarcoma (U-2 OS) cells express both insulin-like growth factor-I (IGF-I) receptors and insulin-like growth factor-II/mannose-6-phosphate (IGF-II/M6P) receptors and synthesize IGF-II: autocrine growth stimulation by IGF-II via the IGF-I receptor. J Cell Physiol 159(3):531–541PubMedCrossRef
11.
Zurück zum Zitat Burrow S, Andrulis IL, Pollak M, Bell RS (1998) Expression of insulin-like growth factor receptor, IGF-1, and IGF-2 in primary and metastatic osteosarcoma. J Surg Onc 69:21–27CrossRef Burrow S, Andrulis IL, Pollak M, Bell RS (1998) Expression of insulin-like growth factor receptor, IGF-1, and IGF-2 in primary and metastatic osteosarcoma. J Surg Onc 69:21–27CrossRef
12.
Zurück zum Zitat Steigen SE, Schaeffer DF, West RB, Nielsen TO (2009) Expression of insulin-like growth factor 2 in mesenchymal neoplasms. Modern Path 22:914–921CrossRef Steigen SE, Schaeffer DF, West RB, Nielsen TO (2009) Expression of insulin-like growth factor 2 in mesenchymal neoplasms. Modern Path 22:914–921CrossRef
13.
Zurück zum Zitat Pollack MN, Polychronakos C, Richard M (1990) Insulin-like growth factor-I: a potent mitogen for human osteogenic sarcoma. J Natl Cancer Inst 82:301–305CrossRef Pollack MN, Polychronakos C, Richard M (1990) Insulin-like growth factor-I: a potent mitogen for human osteogenic sarcoma. J Natl Cancer Inst 82:301–305CrossRef
14.
Zurück zum Zitat Wang Y, Lipari P, Wang X et al (2010) A fully human insulin-like growth factor-I receptor antibody SCH 717454 (Robatumumab) has antitumor activity as a single agent and in combination with cytotoxics in pediatric tumor xenografts. Mol Cancer Ther 9:410PubMedCrossRef Wang Y, Lipari P, Wang X et al (2010) A fully human insulin-like growth factor-I receptor antibody SCH 717454 (Robatumumab) has antitumor activity as a single agent and in combination with cytotoxics in pediatric tumor xenografts. Mol Cancer Ther 9:410PubMedCrossRef
15.
Zurück zum Zitat Tolcher AW, Sarantopoulos J, Patnaik A et al (2009) Phase I, pharmacokinetic and pharmacodynamic study of AMG 479, a fully human monoclo nal antibody to insulin-like growth factor receptor 1. J Clin Oncol 27(34):5800–5807PubMedCrossRef Tolcher AW, Sarantopoulos J, Patnaik A et al (2009) Phase I, pharmacokinetic and pharmacodynamic study of AMG 479, a fully human monoclo nal antibody to insulin-like growth factor receptor 1. J Clin Oncol 27(34):5800–5807PubMedCrossRef
16.
Zurück zum Zitat Olmos D, Postel-Vinay S, Molife LR et al (2010) Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing’s sarcoma: a phase I expansion cohort study. Lancet Oncol 11(2):129–135PubMedCentralPubMedCrossRef Olmos D, Postel-Vinay S, Molife LR et al (2010) Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing’s sarcoma: a phase I expansion cohort study. Lancet Oncol 11(2):129–135PubMedCentralPubMedCrossRef
17.
Zurück zum Zitat Papp AS, Patel S, Crowley J et al (2010) Activity of R1507, a monoclonal antibody to the insulin-like growth factor-1 receptor (IGF1R), in patients (pts) with recurrent or refractory Ewing’s sarcoma family of tumors (ESFT): results of a phase II SARC study. J Clin Oncol 28:15s Papp AS, Patel S, Crowley J et al (2010) Activity of R1507, a monoclonal antibody to the insulin-like growth factor-1 receptor (IGF1R), in patients (pts) with recurrent or refractory Ewing’s sarcoma family of tumors (ESFT): results of a phase II SARC study. J Clin Oncol 28:15s
18.
Zurück zum Zitat Mita MM, Tolcher AW (2007) The role of mTOR inhibitors for treatment of sarcomas. Curr Onc Rep 9:316–322CrossRef Mita MM, Tolcher AW (2007) The role of mTOR inhibitors for treatment of sarcomas. Curr Onc Rep 9:316–322CrossRef
19.
Zurück zum Zitat Dumez H (2008) A phase I–II study of everoilmus (RAD001) in combination with imatinib in patients with imatinib resistant gastrointestinal stromal tumors (GIST). J Clin Oncol 21(10):1990–1998 Dumez H (2008) A phase I–II study of everoilmus (RAD001) in combination with imatinib in patients with imatinib resistant gastrointestinal stromal tumors (GIST). J Clin Oncol 21(10):1990–1998
20.
Zurück zum Zitat Chawla SP, Blay J, Ray-Coquard IL, Cesne AL, Staddon AP, et al. (2011) Results of the phase III, placebo-controlled trial (SUCCEED) evaluating the mTOR inhibitor ridaforolimus (R) as maintenance therapy in advanced sarcoma patients (pts) following clinical benefit from prior standard cytotoxic chemotherapy (CT). J Clin Oncol 29 (suppl; abstr 10005) Chawla SP, Blay J, Ray-Coquard IL, Cesne AL, Staddon AP, et al. (2011) Results of the phase III, placebo-controlled trial (SUCCEED) evaluating the mTOR inhibitor ridaforolimus (R) as maintenance therapy in advanced sarcoma patients (pts) following clinical benefit from prior standard cytotoxic chemotherapy (CT). J Clin Oncol 29 (suppl; abstr 10005)
21.
Zurück zum Zitat O’Reilly KE, Rojo F, She QB, Solit D, Mills GB, Smith D et al (2006) mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 66:1500–1508PubMedCentralPubMedCrossRef O’Reilly KE, Rojo F, She QB, Solit D, Mills GB, Smith D et al (2006) mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 66:1500–1508PubMedCentralPubMedCrossRef
22.
Zurück zum Zitat Quek R, Wang Q, Morgan JA et al (2011) Combination mTOR and IGF-1R inhibition: phase I trial of everolimus and figitumumab in patients with advanced sarcomas and other solid tumors. Clin Cancer Res 17:871–879PubMedCrossRef Quek R, Wang Q, Morgan JA et al (2011) Combination mTOR and IGF-1R inhibition: phase I trial of everolimus and figitumumab in patients with advanced sarcomas and other solid tumors. Clin Cancer Res 17:871–879PubMedCrossRef
Metadaten
Titel
Partial response of a rare malignant metastatic diffuse tenosynovial giant cell tumor with benign histologic features, treated with SCH 717–454, an insulin growth factor receptor inhibitor, in combination with everolimus, an MTOR inhibitor
verfasst von
Swati Sikaria
Josefine Heim-Hall
Elizabeth H. Diaz
Ronald Williams
Kamelesh Sankhala
Brenda Laabs
Monica Mita
Publikationsdatum
01.03.2014
Verlag
Springer International Publishing
Erschienen in
Targeted Oncology / Ausgabe 1/2014
Print ISSN: 1776-2596
Elektronische ISSN: 1776-260X
DOI
https://doi.org/10.1007/s11523-013-0267-8

Weitere Artikel der Ausgabe 1/2014

Targeted Oncology 1/2014 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.